Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Natera Inc . (NASDAQ:NTRA), a $20.55 billion diagnostics company that has delivered a remarkable 60% return over the past year, saw its President of Clinical Diagnostics, Solomon Moshkevich, recently sell shares of the company, according to a filing with the Securities and Exchange Commission. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. On April 28, Moshkevich sold 2,206 shares of Natera’s common stock at an average price of $152.18 per share, amounting to a total transaction value of approximately $335,714. Following this transaction, Moshkevich holds 139,280 shares directly. The company maintains strong financial health with a current ratio of 4.0 and has demonstrated robust revenue growth of 57% in the last twelve months.
In addition to the sale, Moshkevich made a charitable contribution of 75 shares, which did not involve any monetary exchange. This contribution was noted in the filing with a zero-dollar value.
The sale of shares was executed to meet tax obligations related to the vesting of restricted stock units, as outlined in a pre-established trading plan under Rule 10b5-1(c).
In other recent news, Natera Inc. reported its fourth-quarter 2024 financial results, exceeding Wall Street expectations with a revenue of $476 million, a 53% increase from the previous year, and a narrower-than-expected loss per share of -$0.41. Despite these positive results, the company’s stock experienced a decline in regular trading. Analysts at TD Cowen and Canaccord Genuity expressed optimism about Natera’s future, maintaining a Buy rating and setting a price target of $195, citing the company’s strong sales projections and strategic operational expenditures. Furthermore, Natera announced the U.S. launch of its Signatera Genome assay, designed to detect circulating tumor DNA for cancer management, which is supported by a large-scale clinical study presented at the American Society of Clinical Oncology Annual Meeting. In addition, Natera initiated the HEROES clinical trial to explore therapy de-escalation in metastatic HER2+ breast cancer patients, using the Signatera test to guide treatment decisions. These developments reflect Natera’s ongoing efforts to expand its genetic testing capabilities and enhance its market position in oncology diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.